bupivacaine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
local anaesthetics 432 38396-39-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bupivacaine hydrochloride anhydrous
  • bupivacaine
  • (+/-)-Bupivacaine
  • bucain
  • bupivan
  • carbostesin
  • DL-Bupivacaine
  • bupivacaine hydrochloride
  • bupivacaine HCl
A widely used local anesthetic agent.
  • Molecular weight: 288.44
  • Formula: C18H28N2O
  • CLOGP: 3.69
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 32.34
  • ALOGS: -3.47
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.17 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.84 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 3, 1972 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaesthetic complication 1414.49 19.74 263 12954 1467 50590440
Maternal exposure during delivery 560.85 19.74 111 13106 895 50591012
Exposure during pregnancy 539.26 19.74 355 12862 120660 50471247
Drug ineffective 422.29 19.74 755 12462 818578 49773329
Hypotension 379.27 19.74 381 12836 235088 50356819
Local anaesthetic systemic toxicity 237.53 19.74 50 13167 562 50591345
Maternal exposure during pregnancy 235.54 19.74 247 12970 159531 50432376
Chondrolysis 224.18 19.74 40 13177 168 50591739
Cauda equina syndrome 188.87 19.74 43 13174 711 50591196
Bradycardia 163.47 19.74 135 13082 64291 50527616
Incorrect route of product administration 137.81 19.74 76 13141 18590 50573317
Drug withdrawal syndrome 126.95 19.74 80 13137 25001 50566906
Procedural hypotension 119.08 19.74 32 13185 1070 50590837
Normal newborn 109.55 19.74 47 13170 6644 50585263
Extradural haematoma 103.21 19.74 31 13186 1556 50590351
Respiratory depression 102.91 19.74 54 13163 11956 50579951
Implant site extravasation 102.51 19.74 24 13193 451 50591456
Lagophthalmos 96.93 19.74 21 13196 273 50591634
Unresponsive to stimuli 96.61 19.74 73 13144 30536 50561371
Paralysis 91.88 19.74 45 13172 8619 50583288
Wrong product administered 88.90 19.74 38 13179 5322 50586585
Fatigue 84.39 19.74 40 13177 707561 49884346
Diarrhoea 76.93 19.74 29 13188 588447 50003460
Hyperaesthesia 76.49 19.74 39 13178 8134 50583773
Anterior spinal artery syndrome 76.12 19.74 14 13203 72 50591835
Cardiac arrest 75.72 19.74 101 13116 83550 50508357
Medical device site pain 71.45 19.74 15 13202 166 50591741
Inadequate analgesia 69.89 19.74 26 13191 2532 50589375
Premature delivery 69.32 19.74 54 13163 23609 50568298
Caesarean section 67.12 19.74 45 13172 15594 50576313
Sedation 67.02 19.74 59 13158 30551 50561356
Spinal cord injury 64.91 19.74 18 13199 678 50591229
Hypoaesthesia 62.49 19.74 116 13101 127141 50464766
Anaphylactic shock 61.23 19.74 47 13170 20108 50571799
Sensory loss 61.22 19.74 33 13184 7705 50584202
Anaphylactic reaction 59.55 19.74 72 13145 53983 50537924
Rhythm idioventricular 54.76 19.74 12 13205 165 50591742
Labelled drug-drug interaction medication error 54.44 19.74 34 13183 10443 50581464
Generalised tonic-clonic seizure 54.20 19.74 49 13168 26261 50565646
Hypertensive encephalopathy 53.99 19.74 15 13202 569 50591338
Post lumbar puncture syndrome 53.91 19.74 15 13202 572 50591335
Myoclonus 53.53 19.74 38 13179 14432 50577475
Therapeutic product effect prolonged 52.99 19.74 13 13204 300 50591607
Conjunctival oedema 52.56 19.74 15 13202 628 50591279
Meningitis chemical 52.21 19.74 11 13206 124 50591783
Platelet aggregation inhibition 52.13 19.74 11 13206 125 50591782
Spinal anaesthesia 50.39 19.74 9 13208 38 50591869
Hypothermia 50.19 19.74 34 13183 11982 50579925
Post procedural complication 49.81 19.74 37 13180 15067 50576840
Therapeutic product effect delayed 49.63 19.74 19 13198 2002 50589905
Paraplegia 49.47 19.74 20 13197 2434 50589473
No adverse event 49.40 19.74 52 13165 33526 50558381
Haemodynamic instability 49.32 19.74 29 13188 7995 50583912
Blood pressure decreased 48.26 19.74 66 13151 55843 50536064
Procedural pain 48.13 19.74 35 13182 13797 50578110
Parophthalmia 47.92 19.74 12 13205 302 50591605
Overdose 46.56 19.74 89 13128 99638 50492269
Diplegia 46.54 19.74 15 13202 951 50590956
Seizure 46.43 19.74 98 13119 117776 50474131
Alopecia 46.39 19.74 5 13212 245042 50346865
Neurotoxicity 46.14 19.74 35 13182 14705 50577202
Delayed recovery from anaesthesia 45.99 19.74 14 13203 735 50591172
Arachnoid web 45.91 19.74 7 13210 7 50591900
Rash 45.77 19.74 29 13188 437442 50154465
Vascular resistance systemic decreased 43.70 19.74 9 13208 90 50591817
Mental status changes postoperative 43.49 19.74 10 13207 173 50591734
Apnoea 42.35 19.74 25 13192 6941 50584966
Rheumatoid arthritis 41.39 19.74 3 13214 202547 50389360
Loss of consciousness 41.37 19.74 87 13130 104266 50487641
Horner's syndrome 41.06 19.74 7 13210 21 50591886
Muscular weakness 40.95 19.74 82 13135 94931 50496976
Therapy non-responder 40.70 19.74 58 13159 50964 50540943
Circulatory collapse 40.70 19.74 37 13180 19963 50571944
Bradycardia foetal 40.58 19.74 11 13206 380 50591527
Spinal cord infarction 40.42 19.74 10 13207 239 50591668
Pulseless electrical activity 40.15 19.74 24 13193 6817 50585090
Intracranial hypotension 39.84 19.74 10 13207 254 50591653
Arthralgia 39.52 19.74 34 13183 438668 50153239
Motor dysfunction 39.07 19.74 25 13192 8006 50583901
Arachnoiditis 39.05 19.74 10 13207 276 50591631
Abdominal discomfort 38.51 19.74 7 13210 231634 50360273
Pneumonia 38.31 19.74 26 13191 378375 50213532
Uterine atony 37.76 19.74 9 13208 183 50591724
Product quality issue 37.10 19.74 43 13174 30815 50561092
Procedural complication 36.57 19.74 20 13197 4803 50587104
Kounis syndrome 36.01 19.74 13 13204 1162 50590745
Peripartum cardiomyopathy 35.38 19.74 8 13209 128 50591779
Necrotising fasciitis 35.22 19.74 16 13201 2588 50589319
Cerebrospinal fluid leakage 35.02 19.74 12 13205 920 50590987
Live birth 34.65 19.74 31 13186 16377 50575530
Ophthalmoplegia 34.35 19.74 13 13204 1327 50590580
Device infusion issue 34.10 19.74 13 13204 1354 50590553
Nasopharyngitis 33.92 19.74 5 13212 192922 50398985
Joint swelling 33.79 19.74 11 13206 245275 50346632
Strabismus 33.77 19.74 14 13203 1816 50590091
Complication associated with device 33.58 19.74 29 13188 14626 50577281
Death 33.40 19.74 22 13195 325357 50266550
Spinal cord compression 32.68 19.74 17 13200 3692 50588215
Confusion postoperative 32.19 19.74 8 13209 195 50591712
Ventricular tachycardia 31.66 19.74 29 13188 15792 50576115
Exophthalmos 31.58 19.74 12 13205 1238 50590669
Tachycardia 31.51 19.74 76 13141 99687 50492220
Depressed level of consciousness 31.49 19.74 52 13165 51901 50540006
Spinal cord oedema 30.45 19.74 7 13210 121 50591786
Respiratory rate decreased 29.57 19.74 15 13202 3093 50588814
Radiculopathy 28.13 19.74 17 13200 4924 50586983
Arthropathy 27.96 19.74 4 13213 157902 50434005
Pyrexia 27.96 19.74 35 13182 380168 50211739
Medical device site erythema 27.65 19.74 5 13212 23 50591884
Device alarm issue 26.91 19.74 11 13206 1377 50590530
Bundle branch block left 26.90 19.74 18 13199 6212 50585695
Respiratory arrest 26.75 19.74 36 13181 29973 50561934
Myopathy toxic 26.64 19.74 8 13209 401 50591506
Myelitis transverse 26.49 19.74 10 13207 1014 50590893
Device failure 26.37 19.74 17 13200 5511 50586396
Sensory disturbance 26.28 19.74 23 13194 11806 50580101
Cancer pain 26.12 19.74 13 13204 2574 50589333
Product measured potency issue 25.97 19.74 6 13211 106 50591801
Product dose omission issue 25.74 19.74 8 13209 183830 50408077
Uterine hypertonus 25.65 19.74 7 13210 248 50591659
Neuralgia 25.50 19.74 30 13187 21833 50570074
Peripheral swelling 25.40 19.74 11 13206 205925 50385982
Product closure issue 25.34 19.74 4 13213 6 50591901
Chondromalacia 25.03 19.74 7 13210 272 50591635
Infusion site mass 25.01 19.74 10 13207 1182 50590725
Obstetric procedure complication 24.61 19.74 4 13213 8 50591899
Cardiac output increased 24.43 19.74 6 13211 139 50591768
Postpartum haemorrhage 24.43 19.74 11 13206 1743 50590164
Product formulation issue 24.38 19.74 8 13209 537 50591370
Implant site infection 23.97 19.74 9 13208 899 50591008
Acute kidney injury 23.95 19.74 15 13202 228043 50363864
Neutropenia 23.46 19.74 5 13212 147960 50443947
Weight increased 23.03 19.74 12 13205 201879 50390028
Incision site pain 23.03 19.74 9 13208 1002 50590905
Sinusitis 22.86 19.74 8 13209 170550 50421357
Arteriospasm coronary 22.78 19.74 13 13204 3389 50588518
Maternal drugs affecting foetus 22.72 19.74 15 13202 5062 50586845
Cough 22.54 19.74 18 13199 241246 50350661
Allodynia 22.50 19.74 8 13209 684 50591223
Monoplegia 22.38 19.74 12 13205 2771 50589136
Anaesthetic complication cardiac 22.37 19.74 4 13213 17 50591890
General physical health deterioration 22.21 19.74 5 13212 142429 50449478
Blood pressure immeasurable 22.20 19.74 9 13208 1103 50590804
Trigeminal palsy 21.84 19.74 4 13213 20 50591887
Urinary tract infection 21.83 19.74 16 13201 224004 50367903
Sensorimotor disorder 21.82 19.74 7 13210 437 50591470
Contraindicated product administered 21.73 19.74 6 13211 148952 50442955
Arthrofibrosis 21.37 19.74 4 13213 23 50591884
Urinary retention 21.21 19.74 30 13187 26160 50565747
Blood pressure systolic decreased 21.06 19.74 15 13202 5724 50586183
Neuromuscular block prolonged 20.85 19.74 7 13210 504 50591403
Hypoxia 20.68 19.74 43 13174 51080 50540827
White blood cell count decreased 20.56 19.74 3 13214 116719 50475188
Neuromuscular blockade 20.31 19.74 6 13211 284 50591623
Hypovolaemia 20.22 19.74 18 13199 9447 50582460
Neurogenic shock 20.03 19.74 6 13211 298 50591609

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaesthetic complication 637.83 23.66 121 6811 865 29566730
Chondrolysis 259.21 23.66 41 6891 75 29567520
Local anaesthetic systemic toxicity 190.93 23.66 34 6898 161 29567434
Drug withdrawal syndrome 131.21 23.66 70 6862 17914 29549681
Pain 125.49 23.66 176 6756 171256 29396339
Cauda equina syndrome 103.86 23.66 23 6909 374 29567221
Drug ineffective 102.09 23.66 246 6686 362924 29204671
Hypoaesthesia 83.03 23.66 81 6851 53386 29514209
Lagophthalmos 69.17 23.66 13 6919 87 29567508
Incorrect route of product administration 62.18 23.66 36 6896 10765 29556830
Hyperaesthesia 58.09 23.66 24 6908 3445 29564150
Paralysis 56.48 23.66 27 6905 5470 29562125
Medical device site pain 53.60 23.66 10 6922 64 29567531
Spinal cord infarction 50.67 23.66 12 6920 266 29567329
Sinus arrest 49.91 23.66 17 6915 1430 29566165
Myoclonus 48.03 23.66 33 6899 13276 29554319
Device failure 48.02 23.66 18 6914 1998 29565597
Cardiotoxicity 47.82 23.66 23 6909 4721 29562874
Corneal reflex decreased 45.36 23.66 10 6922 159 29567436
Respiratory depression 45.22 23.66 32 6900 13491 29554104
Autonomic nervous system imbalance 45.14 23.66 18 6914 2358 29565237
Sensory loss 44.74 23.66 21 6911 4083 29563512
Paraplegia 44.02 23.66 18 6914 2516 29565079
Anal incontinence 43.33 23.66 24 6908 6591 29561004
Arachnoiditis 43.13 23.66 11 6921 334 29567261
Areflexia 42.57 23.66 18 6914 2736 29564859
Post procedural hypotension 42.25 23.66 8 6924 56 29567539
Implant site extravasation 41.74 23.66 11 6921 381 29567214
Oculocardiac reflex 41.42 23.66 8 6924 63 29567532
Device infusion issue 41.27 23.66 12 6920 600 29566995
Sodium retention 40.88 23.66 8 6924 68 29567527
Bradycardia 39.96 23.66 62 6870 65567 29502028
Spinal shock 39.50 23.66 7 6925 32 29567563
Anal sphincter atony 39.18 23.66 8 6924 86 29567509
Renin increased 38.77 23.66 8 6924 91 29567504
Cardiac arrest 36.47 23.66 69 6863 85522 29482073
Myopathy toxic 35.92 23.66 10 6922 427 29567168
Generalised tonic-clonic seizure 35.41 23.66 32 6900 19107 29548488
Arthrofibrosis 34.93 23.66 7 6925 68 29567527
Loss of consciousness 34.43 23.66 62 6870 73994 29493601
Therapeutic product effect delayed 34.35 23.66 12 6920 1088 29566507
Therapy non-responder 33.96 23.66 39 6893 30872 29536723
Paroxysmal sympathetic hyperactivity 33.75 23.66 6 6926 28 29567567
Amaurosis 32.47 23.66 10 6922 610 29566985
Apnoea 31.60 23.66 19 6913 6083 29561512
Pneumonia 31.58 23.66 18 6914 320154 29247441
Urinary incontinence 31.37 23.66 28 6904 16453 29551142
Infusion site mass 31.11 23.66 8 6924 251 29567344
Electrocardiogram T wave amplitude increased 31.10 23.66 6 6926 47 29567548
Muscle rigidity 30.83 23.66 22 6910 9389 29558206
Sedation 30.06 23.66 28 6904 17377 29550218
Jaundice cholestatic 29.52 23.66 16 6916 4210 29563385
Device power source issue 29.34 23.66 8 6924 316 29567279
Axillary pain 29.31 23.66 8 6924 317 29567278
Paraparesis 28.84 23.66 12 6920 1752 29565843
Hypotension 28.49 23.66 105 6827 194249 29373346
Brief psychotic disorder with marked stressors 28.20 23.66 7 6925 190 29567405
Device malfunction 28.13 23.66 20 6912 8487 29559108
Unresponsive to stimuli 28.10 23.66 32 6900 25094 29542501
Muscular weakness 27.63 23.66 51 6881 62001 29505594
Procedural complication 27.33 23.66 15 6917 4045 29563550
Delayed recovery from anaesthesia 26.93 23.66 9 6923 714 29566881
Complication associated with device 26.46 23.66 16 6916 5175 29562420
Diaphragmatic paralysis 26.41 23.66 8 6924 461 29567134
No adverse event 26.18 23.66 26 6906 17452 29550143
Acute kidney injury 24.61 23.66 16 6916 265251 29302344
Neurotoxicity 24.25 23.66 23 6909 14590 29553005
Mental status changes 24.09 23.66 35 6897 34892 29532703
Procedural pain 24.03 23.66 14 6918 4230 29563365
Spinal cord injury 23.98 23.66 7 6925 355 29567240

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaesthetic complication 1711.65 16.49 331 17162 2248 64478991
Chondrolysis 455.47 16.49 79 17414 258 64480981
Maternal exposure during delivery 425.65 16.49 87 17406 803 64480436
Maternal exposure during pregnancy 296.36 16.49 229 17264 95655 64385584
Drug ineffective 290.57 16.49 674 16819 839573 63641666
Cauda equina syndrome 269.11 16.49 62 17431 1041 64480198
Exposure during pregnancy 265.35 16.49 197 17296 77478 64403761
Drug withdrawal syndrome 236.43 16.49 131 17362 31160 64450079
Local anaesthetic systemic toxicity 218.86 16.49 48 17445 637 64480602
Hypotension 187.06 16.49 354 17139 380620 64100619
Incorrect route of product administration 174.48 16.49 97 17396 23201 64458038
Lagophthalmos 165.70 16.49 34 17459 320 64480919
Bradycardia 154.64 16.49 175 17318 118044 64363195
Paralysis 138.16 16.49 66 17427 11529 64469710
Hyperaesthesia 131.63 16.49 61 17432 9953 64471286
Respiratory depression 129.10 16.49 80 17413 23363 64457876
Implant site extravasation 125.22 16.49 31 17462 715 64480524
Hypoaesthesia 122.64 16.49 169 17324 138939 64342300
Normal newborn 112.33 16.49 46 17447 5571 64475668
Medical device site pain 110.20 16.49 23 17470 237 64481002
Extradural haematoma 109.23 16.49 37 17456 2639 64478600
Unresponsive to stimuli 99.18 16.49 93 17400 50300 64430939
Sensory loss 97.70 16.49 50 17443 10119 64471120
Myoclonus 95.37 16.49 68 17425 25050 64456189
Cardiac arrest 92.99 16.49 157 17336 153907 64327332
Sedation 92.31 16.49 82 17411 41380 64439859
Anterior spinal artery syndrome 92.03 16.49 17 17476 86 64481153
Spinal cord injury 89.37 16.49 25 17468 936 64480303
Inadequate analgesia 87.89 16.49 35 17458 3943 64477296
Spinal cord infarction 87.09 16.49 22 17471 552 64480687
Diarrhoea 81.11 16.49 48 17445 722656 63758583
Paraplegia 80.45 16.49 34 17459 4456 64476783
Apnoea 76.92 16.49 43 17450 10379 64470860
Arachnoiditis 73.66 16.49 20 17473 669 64480570
Wrong product administered 71.39 16.49 37 17456 7683 64473556
No adverse event 70.65 16.49 60 17433 28501 64452738
Anaphylactic reaction 70.56 16.49 90 17403 68574 64412665
Premature delivery 69.81 16.49 50 17443 18539 64462700
Device failure 69.63 16.49 33 17460 5659 64475580
Loss of consciousness 68.91 16.49 135 17358 148230 64333009
Pneumonia 68.82 16.49 33 17460 559543 63921696
Generalised tonic-clonic seizure 67.96 16.49 68 17425 39789 64441450
Fatigue 66.90 16.49 63 17430 748667 63732572
Pain 66.39 16.49 311 17182 553200 63928039
Delayed recovery from anaesthesia 65.81 16.49 22 17471 1506 64479733
Meningitis chemical 63.39 16.49 14 17479 192 64481047
Device infusion issue 62.79 16.49 22 17471 1736 64479503
Anaphylactic shock 61.64 16.49 57 17436 30271 64450968
Post procedural complication 61.48 16.49 49 17444 21304 64459935
Diplegia 60.77 16.49 21 17472 1590 64479649
Muscular weakness 60.49 16.49 117 17376 127221 64354018
Myopathy toxic 60.45 16.49 18 17475 843 64480396
Acute kidney injury 59.12 16.49 24 17469 449216 64032023
Complication associated with device 55.34 16.49 40 17453 15040 64466199
Post lumbar puncture syndrome 55.17 16.49 16 17477 683 64480556
Therapeutic product effect prolonged 54.95 16.49 15 17478 512 64480727
Procedural pain 54.34 16.49 40 17453 15468 64465771
Bradycardia foetal 54.14 16.49 11 17482 98 64481141
Arthrofibrosis 53.27 16.49 11 17482 107 64481132
Spinal anaesthesia 52.55 16.49 10 17483 61 64481178
Post procedural hypotension 52.41 16.49 10 17483 62 64481177
Horner's syndrome 52.20 16.49 9 17484 28 64481211
Procedural complication 50.97 16.49 29 17464 7236 64474003
Platelet aggregation inhibition 50.57 16.49 11 17482 140 64481099
Areflexia 49.20 16.49 25 17468 4982 64476257
Overdose 48.94 16.49 123 17370 159443 64321796
Blood pressure decreased 48.21 16.49 85 17408 86114 64395125
Kounis syndrome 47.92 16.49 21 17472 3004 64478235
Strabismus 47.90 16.49 19 17474 2118 64479121
Hypothermia 47.65 16.49 41 17452 19815 64461424
Hypertensive encephalopathy 47.02 16.49 15 17478 885 64480354
Cancer pain 46.98 16.49 23 17470 4234 64477005
Spinal cord oedema 46.04 16.49 12 17481 342 64480897
Arachnoid web 45.64 16.49 7 17486 7 64481232
Spinal shock 45.25 16.49 8 17485 30 64481209
Ventricular tachycardia 45.17 16.49 51 17442 34214 64447025
Neutropenia 44.79 16.49 6 17487 239618 64241621
Therapeutic product effect delayed 44.59 16.49 19 17474 2540 64478699
Sinus arrest 44.30 16.49 20 17473 3070 64478169
Caesarean section 43.89 16.49 31 17462 11243 64469996
Chondromalacia 43.61 16.49 10 17483 164 64481075
Neurotoxicity 43.51 16.49 45 17448 27359 64453880
Spinal cord compression 43.37 16.49 24 17469 5679 64475560
Rash 42.73 16.49 37 17456 458512 64022727
Death 42.55 16.49 41 17452 482664 63998575
Anal incontinence 41.89 16.49 34 17459 15162 64466077
Allodynia 41.81 16.49 15 17478 1268 64479971
Autonomic nervous system imbalance 41.68 16.49 21 17472 4111 64477128
Parophthalmia 41.60 16.49 11 17482 332 64480907
Seizure 41.45 16.49 119 17374 166773 64314466
Rhythm idioventricular 41.40 16.49 12 17481 511 64480728
Vascular resistance systemic decreased 41.19 16.49 10 17483 212 64481027
Radiculopathy 40.74 16.49 23 17470 5655 64475584
Conjunctival oedema 40.64 16.49 14 17479 1050 64480189
Oculocardiac reflex 40.26 16.49 8 17485 63 64481176
Depressed level of consciousness 40.09 16.49 76 17417 81360 64399879
Monoplegia 39.19 16.49 19 17474 3424 64477815
Mental status changes postoperative 38.73 16.49 9 17484 157 64481082
Uterine atony 38.26 16.49 9 17484 166 64481073
Sensory disturbance 37.36 16.49 30 17463 13178 64468061
Ophthalmoplegia 37.19 16.49 17 17476 2685 64478554
Febrile neutropenia 36.78 16.49 4 17489 187653 64293586
Corneal reflex decreased 36.70 16.49 10 17483 339 64480900
Urinary incontinence 36.51 16.49 47 17446 36104 64445135
Tachycardia 36.50 16.49 106 17387 149473 64331766
Nasopharyngitis 36.42 16.49 5 17488 196068 64285171
Labelled drug-drug interaction medication error 36.42 16.49 37 17456 22025 64459214
Pulseless electrical activity 36.17 16.49 29 17464 12710 64468529
Paraparesis 35.91 16.49 18 17475 3484 64477755
Peripartum cardiomyopathy 35.37 16.49 8 17485 123 64481116
Mental status changes 35.08 16.49 61 17432 61101 64420138
Thrombocytopenia 34.60 16.49 9 17484 223792 64257447
Pyrexia 34.34 16.49 62 17431 558582 63922657
Therapy non-responder 34.30 16.49 63 17430 65836 64415403
Haemodynamic instability 34.18 16.49 30 17463 14882 64466357
Infusion site mass 33.98 16.49 12 17481 969 64480270
Cough 33.85 16.49 20 17473 302128 64179111
Adverse drug reaction 33.78 16.49 51 17442 45413 64435826
Anaemia 33.53 16.49 32 17461 378648 64102591
Rheumatoid arthritis 33.51 16.49 3 17490 164291 64316948
Anaesthetic complication neurological 32.30 16.49 10 17483 535 64480704
Product quality issue 32.08 16.49 40 17453 29759 64451480
Confusion postoperative 31.77 16.49 8 17485 198 64481041
Necrotising fasciitis 31.41 16.49 19 17474 5307 64475932
Motor dysfunction 30.41 16.49 25 17468 11348 64469891
Neuromuscular block prolonged 30.25 16.49 11 17482 966 64480273
General physical health deterioration 30.14 16.49 9 17484 204416 64276823
Diaphragmatic paralysis 29.65 16.49 11 17482 1023 64480216
Decreased appetite 29.60 16.49 20 17473 281269 64199970
Neuralgia 29.56 16.49 36 17457 26148 64455091
Alopecia 29.00 16.49 5 17488 165685 64315554
Diplopia 28.93 16.49 36 17457 26729 64454510
Sensorimotor disorder 28.61 16.49 10 17483 783 64480456
Device power source issue 28.60 16.49 10 17483 784 64480455
Exophthalmos 28.57 16.49 12 17481 1548 64479691
Arteriospasm coronary 28.43 16.49 18 17475 5447 64475792
Drug intolerance 28.22 16.49 8 17485 187984 64293255
Anal sphincter atony 28.16 16.49 8 17485 317 64480922
Medical device site erythema 27.47 16.49 6 17487 78 64481161
Manipulation 27.47 16.49 6 17487 78 64481161
Bezold-Jarisch reflex 27.46 16.49 5 17488 23 64481216
Intracranial hypotension 27.44 16.49 8 17485 348 64480891
White blood cell count decreased 27.11 16.49 5 17488 157832 64323407
Cerebrospinal fluid leakage 27.10 16.49 11 17482 1301 64479938
Circulatory collapse 26.72 16.49 39 17454 33693 64447546
Live birth 26.60 16.49 23 17470 11181 64470058
Respiratory rate decreased 26.43 16.49 16 17477 4475 64476764
Arthralgia 26.34 16.49 50 17443 442210 64039029
Cardiotoxicity 26.26 16.49 22 17471 10252 64470987
Blood pressure immeasurable 26.25 16.49 12 17481 1896 64479343
Product dose omission issue 26.23 16.49 10 17483 194737 64286502
Phrenic nerve paralysis 26.17 16.49 7 17486 221 64481018
Uterine hypertonus 26.02 16.49 7 17486 226 64481013
Amaurosis 25.93 16.49 10 17483 1034 64480205
Brugada syndrome 25.62 16.49 10 17483 1068 64480171
Disease progression 25.41 16.49 4 17489 141676 64339563
Product closure issue 25.19 16.49 4 17489 6 64481233
Hypercapnia 25.06 16.49 19 17474 7675 64473564
Brief psychotic disorder with marked stressors 24.97 16.49 7 17486 264 64480975
Product administration error 24.92 16.49 34 17459 27609 64453630
Myelitis transverse 24.85 16.49 11 17482 1612 64479627
Neuromuscular blockade 24.54 16.49 8 17485 506 64480733
Device malfunction 24.53 16.49 27 17466 17606 64463633
Respiratory arrest 24.29 16.49 48 17445 52937 64428302
Weight increased 24.05 16.49 14 17479 213334 64267905
Sinus tachycardia 23.76 16.49 36 17457 32152 64449087
Harlequin syndrome 23.41 16.49 5 17488 58 64481181
Device alarm issue 23.24 16.49 11 17482 1879 64479360
Rotator cuff syndrome 23.14 16.49 22 17471 12085 64469154
Gastrointestinal haemorrhage 23.14 16.49 4 17489 132308 64348931
Arthropathy 22.66 16.49 3 17490 120964 64360275
Incision site pain 22.49 16.49 12 17481 2642 64478597
Cardiac output increased 22.44 16.49 6 17487 189 64481050
Product measured potency issue 22.20 16.49 6 17487 197 64481042
Sciatic nerve palsy 22.04 16.49 5 17488 78 64481161
Abdominal discomfort 21.96 16.49 11 17482 182311 64298928
Medical device site swelling 21.92 16.49 5 17488 80 64481159
Paresis 21.87 16.49 13 17480 3519 64477720
Trigeminal palsy 21.69 16.49 4 17489 20 64481219
Spherocytic anaemia 21.64 16.49 3 17490 0 64481239
Peroneal nerve palsy 21.57 16.49 15 17478 5306 64475933
Unmasking of previously unidentified disease 21.53 16.49 10 17483 1637 64479602
Systemic toxicity 21.53 16.49 5 17488 87 64481152
Muscle rigidity 21.33 16.49 25 17468 17448 64463791
Extradural abscess 21.27 16.49 9 17484 1182 64480057
Hyponatraemia 21.02 16.49 7 17486 148332 64332907
Joint range of motion decreased 20.87 16.49 26 17467 19317 64461922
Dehydration 20.75 16.49 17 17476 216746 64264493
Toxic anterior segment syndrome 20.59 16.49 11 17482 2428 64478811
Meningitis aseptic 20.57 16.49 15 17478 5715 64475524
Peripheral swelling 20.52 16.49 16 17477 209137 64272102
Pulse absent 20.51 16.49 18 17475 8928 64472311
Arthritis bacterial 20.47 16.49 17 17476 7822 64473417
Injection site joint infection 20.30 16.49 4 17489 30 64481209
Implant site pain 20.17 16.49 10 17483 1890 64479349
Renal impairment 19.79 16.49 6 17487 135011 64346228
Toxicity to various agents 19.74 16.49 167 17326 363346 64117893
Spinal cord haematoma 19.73 16.49 6 17487 302 64480937
Postpartum haemorrhage 19.59 16.49 9 17484 1438 64479801
Spinal cord ischaemia 19.44 16.49 5 17488 135 64481104
Femoral nerve injury 19.27 16.49 4 17489 40 64481199
Underdose 19.22 16.49 29 17464 25800 64455439
Cardiac failure congestive 18.79 16.49 6 17487 130574 64350665
Hepatic enzyme increased 18.64 16.49 6 17487 129937 64351302
Spinal cord disorder 18.59 16.49 9 17484 1617 64479622
Paraesthesia 18.57 16.49 79 17414 134443 64346796
Implant site infection 18.36 16.49 9 17484 1660 64479579
Device kink 18.24 16.49 9 17484 1684 64479555
Blood creatinine increased 18.23 16.49 7 17486 135775 64345464
Sphincter of Oddi dysfunction 18.09 16.49 6 17487 401 64480838
Ventricular fibrillation 18.05 16.49 27 17466 23833 64457406
Tethered cord syndrome 18.03 16.49 3 17490 7 64481232
Maternal use of illicit drugs 18.03 16.49 3 17490 7 64481232
Medication error 17.96 16.49 41 17452 49925 64431314
Medical device site infection 17.86 16.49 6 17487 417 64480822
Implant site swelling 17.86 16.49 6 17487 417 64480822
Medical device site discharge 17.84 16.49 4 17489 59 64481180
Catheter site mass 17.84 16.49 4 17489 59 64481180
Somnolence 17.76 16.49 105 17388 203540 64277699
Femoral nerve palsy 17.72 16.49 4 17489 61 64481178
Device issue 17.67 16.49 26 17467 22622 64458617
Implant site scar 17.60 16.49 5 17488 198 64481041
Urinary retention 17.28 16.49 40 17453 49161 64432078
Weight decreased 17.25 16.49 32 17461 285707 64195532
Jaundice cholestatic 17.04 16.49 16 17477 8654 64472585
Device connection issue 16.90 16.49 7 17486 872 64480367
Medical device site cellulitis 16.81 16.49 3 17490 12 64481227
Stroke volume increased 16.81 16.49 3 17490 12 64481227
Urinary tract infection 16.75 16.49 23 17470 231573 64249666
Meningeal neoplasm 16.62 16.49 3 17490 13 64481226
Hypoaesthesia oral 16.57 16.49 18 17475 11562 64469677

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01BB01 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
ATC N01BB51 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
ATC N01BB59 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA CS M0000897 Amides
CHEBI has role CHEBI:36333 local anesthetics
CHEBI has role CHEBI:37733 EC 3.1.1.8 inhibitor
CHEBI has role CHEBI:37887 adrenergic blockers
CHEBI has role CHEBI:59941 amphiphiles
CHEBI has role CHEBI:60186 SERCA inhibitor
CHEBI has role CHEBI:88188 allergenic drug
MeSH PA D000777 Anesthetics
MeSH PA D000779 Anesthetics, Local
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
FDA EPC N0000175682 Amide Local Anesthetic
FDA PE N0000175976 Local Anesthesia

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anesthesia for cesarean section indication 4847005
Local anesthetic intrathecal block indication 231249005
Skin irritation indication 367466007
Local anesthesia indication 386761002
Itching of skin indication 418363000
Minor Skin Wound Pain indication
Major Nerve Block for Surgery indication
Regional Anesthesia for Surgery indication
Regional Anesthesia for Labor Pain indication
Regional Anesthesia for Ophthalmologic Surgery indication
Regional Anesthesia for Postoperative Pain indication
Local Anesthesia for Ophthalmologic Procedure indication
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Alcohol withdrawal delirium contraindication 8635005
Sinus tachycardia contraindication 11092001
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Asthenia contraindication 13791008
Constipation contraindication 14760008 DOID:2089
Chronic disease of respiratory system contraindication 17097001
Mood swings contraindication 18963009
Myocardial infarction contraindication 22298006 DOID:5844
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Alcohol intoxication contraindication 25702006
Complete atrioventricular block contraindication 27885002
Shock contraindication 27942005
Hypovolemia contraindication 28560003
Hypercapnia contraindication 29596007
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Decreased cardiac function contraindication 43650005
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Stokes-Adams syndrome contraindication 46935006
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Atrial fibrillation contraindication 49436004 DOID:0060224
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Sinus bradycardia contraindication 49710005
Bleeding hemorrhoids contraindication 51551000
Paralytic ileus contraindication 55525008 DOID:8442
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Cerebral arteriosclerosis contraindication 65312002
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Diabetes mellitus contraindication 73211009 DOID:9351
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Urethral stricture contraindication 76618002
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Cor pulmonale contraindication 83291003 DOID:8515
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of mucous membrane contraindication 95351003
Disorder of biliary tract contraindication 105997008 DOID:9741
Acute abdominal pain contraindication 116290004
Procedure on urinary system contraindication 118677009
Open wound contraindication 125643001
Neoplasm of brain contraindication 126952004 DOID:1319
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Drug-induced psychosis contraindication 191483003 DOID:1742
Angina pectoris contraindication 194828000
Primary dilated cardiomyopathy contraindication 195021004
Partial atrioventricular block contraindication 195039008
Disease of liver contraindication 235856003 DOID:409
Morbid obesity contraindication 238136002 DOID:11981
Sepsis syndrome contraindication 238150007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Exacerbation of asthma contraindication 281239006
Lesion of brain contraindication 301766008
Deficiency of cholinesterase contraindication 360607009
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Operation on gastrointestinal tract contraindication 386621005
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Central nervous system depression contraindication 418072004
Denuded skin contraindication 418242004
Dysfunction of sphincter of Oddi contraindication 430887001
Acute exacerbation of asthma contraindication 708038006
Reduced Hepatic Blood Flow contraindication
Lidocaine Toxicity contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Regional postoperative analgesia after onychocomy Indication
Dogs Local postoperative analgesia for cranial cruciate ligament surgery Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Nocita Elanco US Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic
pKa2 7.92 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
660MG/5ML (132MG/ML) POSIMIR INNOCOLL N204803 Feb. 1, 2021 RX SOLUTION, EXTENDED RELEASE INFILTRATION 8153661 Sept. 15, 2025 METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
660MG/5ML (132MG/ML) POSIMIR INNOCOLL N204803 Feb. 1, 2021 RX SOLUTION, EXTENDED RELEASE INFILTRATION 8753665 Sept. 15, 2025 METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
660MG/5ML (132MG/ML) POSIMIR INNOCOLL N204803 Feb. 1, 2021 RX SOLUTION, EXTENDED RELEASE INFILTRATION 8846072 Sept. 15, 2025 METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
100MG XARACOLL INNOCOLL PHARMS N209511 Aug. 28, 2020 RX IMPLANT IMPLANTATION RE47826 May 20, 2029 A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11253504 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9592227 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9913909 March 13, 2034 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10098957 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10213510 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10632199 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 10898575 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083730 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 11083797 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9694079 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR 9801945 April 20, 2035 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11033495 Jan. 22, 2041 METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11179336 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11278494 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11304904 Jan. 22, 2041 METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11311486 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11033495 Jan. 22, 2041 METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11179336 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11278494 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11304904 Jan. 22, 2041 METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION 11311486 Jan. 22, 2041 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG XARACOLL INNOCOLL PHARMS N209511 Aug. 28, 2020 RX IMPLANT IMPLANTATION Aug. 28, 2023 NEW PRODUCT
660MG/5ML (132MG/ML) POSIMIR INNOCOLL N204803 Feb. 1, 2021 RX SOLUTION, EXTENDED RELEASE INFILTRATION Feb. 1, 2024 NEW PRODUCT
133MG/10ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION March 22, 2024 NEW PATIENT POPULATION
266MG/20ML (13.3MG/ML) EXPAREL PACIRA PHARMS INC N022496 Oct. 28, 2011 RX INJECTABLE, LIPOSOMAL INJECTION March 22, 2024 NEW PATIENT POPULATION
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR May 12, 2024 NEW PRODUCT
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR May 12, 2024 NEW PRODUCT
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 RX SOLUTION, EXTENDED RELEASE PERIARTICULAR May 12, 2024 NEW PRODUCT
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) ZYNRELEF KIT HERON THERAPS INC N211988 May 12, 2021 DISCN SOLUTION, EXTENDED RELEASE PERIARTICULAR May 12, 2024 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium channel protein type 4 subunit alpha Ion channel BLOCKER IC50 6 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.66 CHEMBL
Sodium channel protein type 1 subunit alpha Ion channel IC50 5.29 WOMBAT-PK
Prostaglandin E2 receptor EP1 subtype GPCR IC50 5.51 WOMBAT-PK
Cytochrome P450 2D6 Enzyme IC50 6.40 DRUG MATRIX
5-hydroxytryptamine receptor 3A Ion channel IC50 4.23 WOMBAT-PK
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 4.50 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 5 Ion channel BLOCKER Kd 5.40 IUPHAR
Potassium channel subfamily K member 3 Ion channel IC50 4.39 CHEMBL
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 5.66 IUPHAR
Potassium voltage-gated channel subfamily D member 3 Ion channel BLOCKER IC50 4.50 IUPHAR
Potassium channel subfamily K member 3 Ion channel IC50 4.39 CHEMBL
Potassium channel subfamily K member 9 Ion channel IC50 4 CHEMBL

External reference:

IDSource
4019643 VUID
N0000147736 NUI
D07552 KEGG_DRUG
18010-40-7 SECONDARY_CAS_RN
73360-54-0 SECONDARY_CAS_RN
1375412 RXNORM
C0006400 UMLSCUI
CHEBI:3215 CHEBI
CHEMBL1098 ChEMBL_ID
DB00297 DRUGBANK_ID
CHEMBL1200396 ChEMBL_ID
D002045 MESH_DESCRIPTOR_UI
C472824 MESH_SUPPLEMENTAL_RECORD_UI
2474 PUBCHEM_CID
2397 IUPHAR_LIGAND_ID
2279 INN_ID
Y8335394RO UNII
3621 MMSL
39700 MMSL
4305 MMSL
d00180 MMSL
001341 NDDF
005054 NDDF
24022008 SNOMEDCT_US
27196008 SNOMEDCT_US
387150008 SNOMEDCT_US
4018244 VANDF
4019643 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9328 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 25 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9329 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 25 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9330 INJECTION, SOLUTION 2.50 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9331 INJECTION, SOLUTION 5 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9332 INJECTION, SOLUTION 7.50 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9333 INJECTION, SOLUTION 2.50 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9334 INJECTION, SOLUTION 5 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9335 INJECTION, SOLUTION 7.50 mg EPIDURAL ANDA 24 sections
Bupivacaine Hydrochloride with Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0264-9379 INJECTION 7.50 mg SUBARACHNOID ANDA 22 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0557 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 19 sections
Vivacaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9011 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 19 sections
Vivacaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9011 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 19 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9826 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 17 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9827 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 10 sections
Bupivacaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-9828 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 12 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9906 INJECTION, SOLUTION 2.50 mg EPIDURAL NDA 14 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9907 INJECTION, SOLUTION 5 mg EPIDURAL NDA 17 sections
MARCAINE WITH EPINEPHRINE HUMAN PRESCRIPTION DRUG LABEL 2 0404-9908 INJECTION, SOLUTION 2.50 mg INFILTRATION NDA 11 sections
Sensorcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9945 INJECTION, SOLUTION 2.50 mg INFILTRATION NDA 10 sections
Sensorcaine MPF HUMAN PRESCRIPTION DRUG LABEL 1 0404-9946 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 11 sections
Sensorcaine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9947 INJECTION, SOLUTION 5 mg PERINEURAL NDA 11 sections
BUPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0409-1159 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 12 sections
BUPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0409-1159 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 12 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1160 INJECTION, SOLUTION 2.50 mg INFILTRATION ANDA 28 sections
BUPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0409-1162 INJECTION, SOLUTION 5 mg INTRACAUDAL ANDA 12 sections
BUPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0409-1162 INJECTION, SOLUTION 5 mg INTRACAUDAL ANDA 12 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1163 INJECTION, SOLUTION 5 mg PERINEURAL ANDA 28 sections
Bupivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1165 INJECTION, SOLUTION 7.50 mg EPIDURAL ANDA 28 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0409-1559 INJECTION, SOLUTION 2.50 mg EPIDURAL NDA 28 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 1 0409-1560 INJECTION, SOLUTION 5 mg EPIDURAL NDA 28 sections